Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azéane is a topical dermatological cream containing 15% azelaic acid, developed by Laboratoire ACM for the management of skin imperfections associated with acne and rosacea. Azelaic acid is a naturally occurring dicarboxylic acid that provides a multi-modal therapeutic approach. It acts as an antibacterial agent by inhibiting the protein synthesis of *Cutibacterium acnes* and *Staphylococcus epidermidis*. As a keratolytic agent, it normalizes the keratinization process, thereby reducing the formation of comedones. In the context of rosacea, azelaic acid exerts anti-inflammatory effects by downregulating the expression of pro-inflammatory mediators such as kallikrein-5 and cathelicidin, and by scavenging reactive oxygen species. Additionally, it is a competitive inhibitor of tyrosinase, which helps in reducing post-inflammatory hyperpigmentation and melasma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azéane.